|
 For more information please contact:
Kevin McGrath
212.245.4577
Kevin@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar »
|
|
DARA Biosciences, Inc. (NASDAQ: DARA)
DARA BioSciences, Inc. ("DARA") is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.
|
December 20, 2011
DARA BioSciences Reports Appointment of Steve Gorlin as a Director and Designation of David J. Drutz as President and Chief Executive Officer
- downloadp pdf (32 kb) »
|
December 7, 2011
DARA BioSciences Reports Management Changes
- download pdf (27 kb) »
|
November 2, 2011
Selected to Present at Conferences
- download pdf (33 kb) »
|
November 1, 2011
Announces Positive Results From a Successfully Completed Phase 1b Clinical Study
- download pdf (38 kb) »
|
October 10, 2011
KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer According to Findings Published in the Journal of Pain and Symptom Management
- download pdf (113 kb) »
|
September 6, 2011
DARA BioSciences to Present at Rodman & Renshaw Annual Global Healthcare Investment Conference
- download pdf (32 kb) »
|
August 18, 2011
DARA BioSciences Receives Designation from U.S. FDA for KRN5500 - Treatment of Chemotherapy-Induced Neuropathic Pain in Caner Patients
- download pdf (72 kb) »
|
May 3, 2011
NHS National Innovation Centre Identifies Celution(R) as Cost-Effective Innovative Technology for Partial Breast Reconstruction
- download pdf (24 kb) »
|
November 2, 2010:
DARA BioSciences Awarded Grants Totaling Approximately $500,000 for Its Two Drugs Advancing Through Clinical Studies
- download word.doc (40 Kb) »
|
October 25, 2010:
DARA BioSciences Signs Definitive Agreement to Raise $1.4 Million in Registered Direct Offering
- download word.doc (40 Kb) »
|
September 8, 2010:
DARA Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer
- download word.doc (40 Kb) »
|
July 1, 2010:
DARABiosciences, Inc. Announces it is Indefinitely Suspending its Public Unit Offering
- download word.doc (40 Kb) »
|
June 28, 2010:
DARA BioSciences Reports on SurgiVision Receiving FDA Clearance to Market Its ClearPoint System
- download word.doc (40 Kb) »
|
April 27, 2010:
DARA BioSciences Enters Into a Clinical Trial Collaboration With the Division of Cancer Prevention (DCP), National Cancer Institute (NCI) for the Clinical Development of KRN5500
- download word.doc (40 Kb) »
|
April 20, 2010:
DARA BioSciences to Present Results of a Phase 2 Clinical Study for KRN5500 at the "Third International Congress on Neuropathic Pain"
- download word.doc (40 Kb) »
|
March 25, 2010:
DARA BioSciences Initiates a Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
- download word.doc (40 Kb) »
|
March 19, 2010:
DARA Receives Anticipated Notice of Non-Compliance From NASDAQ
- download word.doc (40 Kb) »
|
March 1, 2010:
DARA BioSciences Closes at Market Private Placement Transaction
- download word.doc (40 Kb) »
|
December 23, 2009:
DARA BioSciences Reports on SurgiVision's Filing of a Registration Statement With the Securities and Exchange Commission for an Initial Public Offering (IPO)
- download word.doc (40 Kb) »
|
November 23, 2009:
DARA BioSciences Presented Results of Its Phase 2 Study for KRN5500 at the "12th International Conference on the Mechanisms and Treatment of Neuropathic Pain"
- download word.doc (40 Kb) »
|
November 4, 2009:
DARA BioSciences Secures Additional Intellectual Property Relating to Spicamycin
- download word.doc (40 Kb) »
|
October 22, 2009:
DARA BioSciences Regains NASDAQ Compliance
- download word.doc (40 Kb) »
|
October 13, 2009:
DARA BioSciences Signs Definitive Agreement to Raise Approximately $750,000 in Registered Direct Offering
- download word.doc (40 Kb) »
|
October 12, 2009:
DARA BioSciences and America Stem Cell Broaden Collaboration
- download word.doc (40 Kb) »
|
September 18, 2009:
DARA BioSciences Signs Definitive Agreement to Raise $1.2155 Million in Registered Direct Offering
- download word.doc (40 Kb) »
|
September 17, 2009:
DARA BioSciences Announces Receipt of NASDAQ Letter Citing Non-Compliance with Minimum Bid Price Rules
- download word.doc (40 Kb) »
|
September 15, 2009:
DARA BioSciences Will Present Phase 2a Study Results for KRN5500 at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain Meeting
- download word.doc (40 Kb) »
|
September 11, 2009:
Dara Biosciences Signs Definitive Agreement To Raise $2.5 Million In Registered Direct Offering
- download word.doc (40 Kb) »
|
